title: Upregulation of sestrin-2 expression via P53 protects against 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity.
abstract: Sestrin-2 (SESN2) is a conserved antioxidant protein that is activated upon oxidative stress and protects cells against reactive oxygen species (ROS). However, the role of SESN2 in neurodegenerative diseases, especially in Parkinson's disease (PD), has not yet been elucidated. In this study, we found that expression of SESN2 is elevated in the midbrain of patients with PD. Moreover, in vitro experiments display that the drug 1-methyl-4-phenylpyridinium (MPP+) induces the expression of SESN2 in SH-SY5Y cells in a time- and dose-dependent manner. Our results show that p53 is activated by MPP+. Importantly, inhibition of p53 using small RNA interferences abolishes the increased SESN2 levels induced by MPP+, suggesting that the inductive effect of MPP+ on SESN2 is mediated by p53. Furthermore, knockdown of SESN2 using small RNA interferences promotes MPP+-related neurotoxicity by attenuating oxidative stress, mitochondrial dysfunction, and apoptosis. All these data imply that the induction of SESN2 produces a protective effect in PD.
authors: Daixing
authors: D
authors: Zhou
authors: Chengye
authors: C
authors: Zhan
authors: Qiang
authors: Q
authors: Zhong
authors: Shusheng
authors: S
authors: Li
mesh_terms: D015655:1-Methyl-4-phenylpyridinium / Q000633:toxicity*; D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D008297:Male; D053078:Membrane Potential, Mitochondrial; D008636:Mesencephalon / Q000378:metabolism / Q000473:pathology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism*; D018384:Oxidative Stress; D010300:Parkinson Disease / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation; D000084622:Sestrins
chemical_list: D015655:1-Methyl-4-phenylpyridinium; D009687:Nuclear Proteins; D016159:Tumor Suppressor Protein p53; C465398:SESN2 protein, human; D000084622:Sestrins
references: Free Radic Biol Med. 2012 Sep 15;53(6):1279-85
references: 22841759
references: Nat Protoc. 2007;2(1):141-51
references: 17401348
references: EMBO J. 2012 Jun 26;31(14):3038-62
references: 22735187
references: Science. 2004 Apr 23;304(5670):596-600
references: 15105503
references: Science. 2010 Mar 5;327(5970):1223-8
references: 20203043
references: J Neuroimmune Pharmacol. 2012 Sep;7(3):579-90
references: 22450766
references: Exp Mol Med. 2003 Oct 31;35(5):403-11
references: 14646594
references: Cent Nerv Syst Agents Med Chem. 2010 Dec 1;10(4):278-86
references: 20868359
references: Cell Cycle. 2009 May 15;8(10):1571-6
references: 19377293
references: Nat Neurosci. 2008 Apr;11(4):476-87
references: 18344994
references: Neuron. 2003 Sep 11;39(6):889-909
references: 12971891
references: FEBS Lett. 2009 Nov 3;583(21):3531-5
references: 19822145
references: Cell Signal. 2011 Jun;23(6):963-8
references: 20969953
references: Oncogene. 2002 Sep 5;21(39):6017-31
references: 12203114
references: J Neurochem. 1986 May;46(5):1501-7
references: 3485701
references: Neuroscience. 2012 Jun 1;211:51-76
references: 22108613
references: Ann Neurol. 2002 Nov;52(5):597-606
references: 12402257
references: PLoS One. 2012;7(9):e44610
references: 22970265
references: Cell. 2008 Aug 8;134(3):451-60
references: 18692468
references: Annu Rev Neurosci. 1988;11:81-96
references: 3129982
references: FEBS Lett. 2011 Jun 23;585(12):1853-8
references: 21536039
references: Life Sci. 1985 Jul 1;36(26):2503-8
references: 2861548